Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is a promising biotechnology company with a strong focus on developing transformative therapeutics for the treatment of retinal diseases. Their proprietary Antibody Biopolymer Conjugate (ABC) platform has shown positive results in various studies for different investigational medicines, including tarcocimab tedromer, KSI-501, and KSI-101. These three potential therapies hold high potential to address unmet medical needs and have shown promising results in clinical trials. The recent positive data from the Phase 3 GLOW2 study for Zenkuda in patients with non-proliferative diabetic retinopathy (NPDR) is a significant milestone for the company and has boosted our confidence in the potential of their ABC platform. The company's pipeline also includes other promising investigational medicines with upcoming pivotal data readouts that could serve as important catalysts for the stock. Furthermore, Kodiak Sciences has a strong financial position, with projected operational runway into 2027, reducing any financing risks for the company. The only potential risks to our positive outlook are if the developmental candidates fail to achieve peak commercial revenue estimates or if the company fails to secure capital resources.

Bears say

Kodiak Sciences is highly dependent on the success of its investigational medicines, particularly tarcocimab tedromer (Zenkuda or tarcocimab), which has not consistently shown efficacy in the clinic. There are also potential risks in the manufacturing of multi-component molecules, and the company may struggle to build a global sales and marketing infrastructure for commercialization without significant cash burn. While the success of the ABC platform is supported by positive results from the GLOW2 study, there are still uncertainties surrounding its efficacy and longer-term data for safety, making the outlook for Kodiak Sciences' stock negative.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Jun 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.